CHP Seminar - Martin Eden
Evaluating the economic benefits of complex interventions: accounting for non-health effects of genomic-based diagnostic information
Presenter: Martin Eden
Thursday 15th August 2.30pm–3.30pm Seminar Room 515, Level 5 207 Bouverie Street, Carlton
The receipt of diagnostic information from a genomic test can result in both health and non-health impact. Current applications of cost-effectiveness analysis (CEA) do not take into account non-health value deriving from genomic-based diagnostic information. For my PhD, I undertook a meta-synthesis of qualitative evidence to develop a taxonomy of this non-health value. This provided a starting point for further qualitative work to design a discrete choice experiment (DCE). Findings from the DCE demonstrated that people are willing to trade-off between health and non-health outcomes of genomic test information. The quantification of these trade-offs could be used to refine CEA methods in this context. This work has implications for the economic evaluation of complex precision medicine interventions comprising a diagnostic component.
Martin Eden joined the University of Manchester in 2004 and has worked on evaluations of complex interventions applied to issues of patient safety (PINCER Trial) and self-management of long-term conditions (WISE Study). His work as a health economist has focussed on the evaluation of clinical genetics services. Martin is currently part of a multidisciplinary team, including researchers from QIMR - Brisbane, looking at the impact of policy-level interventions to reduce harm from non-solar ultraviolet radiation. In 2015 Martin was awarded a Doctoral Research Fellowship from the National Institute for Health Research. His presentation will highlight findings from his mixed-methods PhD project.